ofatumumab
Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis
August 30, 2019Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma
Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …
Phase III trials to start in Novartis/Genmab multiple sclerosis collaboration
June 2, 2016Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, ofatumumab, phase III
Genmab (NASDAQ: GEN) has announced that its collaboration partner, Novartis, is set to initiate Phase III trials for ofatumumab in …
Arzerra approved by US FDA for leukaemia
January 20, 2016Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application
The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …
Genmab pulls plug on Phase III Arzerra trial
November 24, 2015Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure
Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …
Novartis buys rights to GSK MS drug for up to $1 billion
August 21, 2015Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab
Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
Trial results back NICE decision on Novartis cancer drug
April 15, 2015Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab
Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …
GSK settles cancer patent dispute
March 28, 2012Research and Development, Sales and Marketing GSK, Genmab, Roche, ofatumumab, patents
GlaxoSmithKline has settled a long-running patent dispute over its cancer treatment ofatumumab. The US patents, which relate to recombinant antibody …
GSK switches to subcutaneous route for antibody
September 16, 2010Research and Development Arzerra, Genmab, GlaxoSmithKline, ofatumumab
GlaxoSmithKline says it will switch development of a new antibody treatment to a subcutaneous injection, to make it more commercially …
Latest content
FibroFind appoints Lee Borthwick as CEO
